This page contains brief details about the drug , it's indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Background and Date of Approval
The U.S. FDA-approved Gliclazide + Metformin for type 2 diabetes on 22nd October 1998. Gliclazide + Metformin belongs to the medication class known as an anti-diabetic which is used to treat type 2 diabetes by controlling the blood sugar levels.
Mechanism of Action of undefined
Gliclazide, a sulfonylurea, helps the pancreas in releasing more insulin to reduce blood glucose levels. Metformin, a biguanide, reduces glucose production in the liver, slows glucose absorption in the intestines, and improves insulin sensitivity in the body.
Uses of undefined
Gliclazide + Metformin is used to manage type 2 diabetes (non-insulin-dependent diabetes mellitus) when diet, exercise, or single-drug therapy is insufficient in controlling the condition.
undefined Drug administaration and Dosage available
Take the Gliclazide + Metformin as your physician advises. Usually, the tablets will be taken during or before food. Do not crush, chew, or open the medicine. Your physician will decide the correct dosage and duration based on age, body weight, and disease condition. Only stop taking the tablet if your doctor advises you to stop.
Warnings, Precautions and Side Effects of undefined
Warnings
Gliclazide + Metformin should not be consumed if you are allergic to Gliclazide + Metformin or any of its ingredients in the medication. Do not take this medicine if you have diabetic ketoacidosis (where the body produces excess blood acids), pre-coma, kidney failure, or dysfunction. Inform your doctor if you have acute conditions that may affect kidney function, such as dehydration, shock, or severe infection. Notify your doctor if you have conditions that can reduce oxygen supply to tissues, such as heart failure or respiratory failure. Avoid consuming this medicine if you have liver failure, ongoing treatment with miconazole, or breastfeeding.
Precautions
Notify your doctor if you are pregnant, planning to get pregnant, or think you may be pregnant or breastfeeding. This medicine is not advised to use in children under 18 years old. The dosage adjustment is needed for patients with kidney problems. It is important to avoid drinking alcohol while taking Gliclazide + Metformin as it can increase the risk of experiencing lactic acidosis and low blood sugar levels. Before starting the treatment, inform your doctor if you have kidney, heart, or liver disease and if you are undergoing radiologic studies that involve the use of iodinated contrast materials given through a vein. This is because these materials can affect kidney function in some cases.
Side Effects
The most common side effects of Gliclazide + Metformin are low blood glucose levels (hypoglycemia), vomiting, a metallic taste in the mouth, nausea, diarrhea, stomach pain, and constipation.
Word Of Advice
Patients should continue to follow their daily carbohydrate intake, while overweight individuals should continue their energy-restricted diet. Monitor your blood sugar levels regularly as your doctor advises, and maintain a balanced diet and exercise routine while taking Gliclazide + Metformin to manage your blood sugar levels effectively. Patients with kidney disorders should consume this medicine cautiously.
Notify your doctor if you have acute alcohol intoxication. Inform about all the underlying medical conditions. Do not stop Gliclazide + Metformin until your doctor advises. Do not double-dose the medicine to make up for a forgotten dose. Notify your doctor if you experience any serious side effects. Your medical professional will inform you if you need any dose adjustments. Contact your doctor for more information.
Frequently Asked Question
References
- Windlas Biotech Ltd, [Accessed on 29th June 2023],*Zuker-MF PI (biocon.com)
- Torrent Pharmaceuticals Ltd, [Revised on January 2016] [Accessed on 29th June 2023], 1995.pdf (torrentian.com)
- Bristol-Myers Squibb Company, US Food and Drug Administration, [Accessed on 29th June 2023], label (fda.gov)
Disclaimer
The drug information on this page is not a substitute for medical advice. It is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you are eligible to receive this treatment.
